Dicerna Pharmaceuticals Hits New 1-Year Low at $15.00 (DRNA)
Dicerna Pharmaceuticals (NASDAQ:DRNA)’s share price reached a new 52-week low during trading on Thursday , American Banking News reports. The stock traded as low as $15.00 and last traded at $15.09, with a volume of 73,628 shares trading hands. The stock had previously closed at $15.79.
A number of analysts have recently weighed in on DRNA shares. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Wednesday, May 14th. They now have a $44.00 price target on the stock, down previously from $53.00. Analysts at Leerink Swann cut their price target on shares of Dicerna Pharmaceuticals from $60.00 to $48.00 in a research note on Wednesday, May 14th. They now have an “outperform” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $44.33.
The stock’s 50-day moving average is $18.20 and its 200-day moving average is $25.01. The company’s market cap is $268.0 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($1.02) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.52) by $0.50. On average, analysts predict that Dicerna Pharmaceuticals will post $-2.27 earnings per share for the current fiscal year.
Dicerna Pharmaceuticals, Inc is a biopharmaceutical company. The Company focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.